


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

1 of 21

Complete if Known	
Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
			0 113 431A	EP		07/18/84		
			0313 156	EP		04/26/89		
			O 88/09932	PCT		06/03/88		
			O 91/17171	PCT		11/14/91		
			WO 91/11718	PCT		08/08/91		
			WO 94/02445	PCT		02/03/94		
			WO 94/02589	PCT		02/03/94		

Examiner's Signature _____ **Date Considered** _____

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.** SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the IDS of 1/21/1999

LAC 5/5/08

490519.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			
(use as many sheets as necessary)			
			
Sheet 2 of 21			
Complete if Known			
Application Number		08/781,296	
Filing Date		January 13, 1997	
First Named Inventor		John B. Harley et al.	
Group Art Unit		Not yet assigned	
Examiner Name		Not yet assigned	
Attorney Docket Number		OMRF 161	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2
PATENT & TRADEMARK OFFICE

Sheet 2
© TRADEMARK O

of

21

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

~~Burden Your Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.~~

Not considered. Identical to the considered IDS of 1/21/1999
LAC 5/5/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

FEB 9 1998
PATENT & TRADEMARK OFFICE

Sheet 3 of 21

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue-number(s), publisher, cit and/or country where published	T ²
		Alexander, et al., "Anti-Ro/SS-A Antibodies in the Pathophysiology of Congenital Heart Block in Neonatal Lupus Syndrome, and Experimental Model," <u>Arth. And Rheum.</u> 35:176-189 (1992)	
		Banerjee, et al., "Complete Nucleotide Sequence of the mRNA Coding for the N Protein of Vesicular Stomatitis Virus (New Jersey Serotype)," <u>Virology</u> 137:432-438 (1984)	
		Baraket, et al., "IgG Antibodies From Patients with Primary Sjogren's Syndrome and systemic Lupus Erythematosus Recognize Different Epitopes in 60-kD SSA/Ro Protein," <u>Clin. Exp. Immunol.</u> 89:38-45 (1992)	
		Baraket, et al., "Mapping of Epitopes on U1 snRNP Polypeptide A with Synthetic Peptides and Autoimmune Sear," <u>Clin. Exp. Immunol.</u> 86(1):71-78 (October, 1991)	
		Baraket, et al., "Recognition of Synthetic Peptides of Sm-D Autoantigen by Lupus Sera," <u>Clin. Exp. Immunol.</u> 81:256-262 (1990)	
		Ben-Chetrit, et al., "Isolation and Characterization of a August 3, 1987 cDNA Encoding the 60-kD Component of the Human SS-A/Ro Ribonucleoprotein Autoantigen," <u>J. Clin. Inv.</u> 83:1284-1292	
		Blank, M., et al., "The Effect of the Immunomodulator Agent AS101 on Interleukin-2 Production in Systemic Lupus Erythematosus (SLE) Induced in Mice by Pathogenic Anti-DNA Antibody," <u>Clin. Exp. Immunol.</u> 79:443-447 (1990)	
		Blank, M., et al., "Induction of SLE-Like Disease in Naive Mice with a Monoclonal anti-DNA Antibody Derived from a Patient with Polymyositis carrying the 16/6 id," <u>J. Autoimmunity</u> 2:683-691 (1988)	
		Blank, M., et al., "Sex Hormone Involvement in the Induction of Experimental Systemic Lupus Erythematosus by a Pathogenic anti-DNA Idiotype in Naive Mice," <u>J. Rheumatol.</u> 17:311-317 (1990)	
		Blank, M., et al., "Induction of Experimental Anti-phospholipid Syndrome Associated with SLE Following Immunization with Human Monoclonal Pathogenic Anti-DNA Idiotype," <u>J. Autoimmunity</u> 5:495-509 (1992)	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of 1/21/1999
LAC 5/5/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161



Sheets 4 of 21

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue/number(s), publisher, cit and/or country where published	T ²
		Blank, M., et al., "Induction of Systemic Lupus Erythematosus in Naive Mice with T-cell Lines Specific for Human Anti-DNA Antibody SA-1 (16/6 Id +) and for Mouse Tuberculosis Antibody TB/68 (16/6 id +)" <u>Clin. Immunol. Immunopathol.</u> 60:471-483 (1991)	
		Bray, et al., "Epstein-Barr Virus Infection and Antibody Synthesis in Patients With Multiple Sclerosis", <u>Arch. Neurology</u> , 40:406-408 (1983)	
		Bray, et al., <u>Arch. Neurol.</u> , (1982)	
		Buyon, "Neonatal Lupus Syndrome," <u>Burr. Opin. In Rheum.</u> 6:523-529 (1994)	
		Chambers, J. et al., "Genomic Structure and Amino Acid Sequence Domains of the Human La Autoantigen," <u>J. Biol. Chem.</u> , 263:18043-18051 (1988)	
		Chambers, J., et al., "Isolation and analysis of cDNA Clones Expressing Human Lupus La Antigen," <u>Proc. Natl. Acad. Sci. USA</u> 82:2115-2119 (1985)	
		Chen, E.K.L., et al., "Ribonucleoprotein SS-B/La belongs to a Protein Family with Consensus Sequences for RNA Binding," <u>Nucl. Acids Res.</u> 17:2233-2244 (1989)	
		Cohen, "The Self, the World and Autoimmunity," <u>Scientific American</u> 258:52-60 (1988)	
		Craft, et al., "Murine and Drosophila B Proteins of SM snRNPs," <u>Mol. Biol. Rep.</u> , 15:159 (1991)	
		Crone, e al., "Viral Transcription is Necessary and Sufficient for Vesicular Stomatitis Virus to Inhibit Maturation of Small Nuclear Ribonucleoproteins," <u>Journal of Virology</u> 63(10):4172-4180 (1989)	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Not considered. Identical to the considered IDS of 1/21/1999
LAC 5/5/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)



Sheet

5

of

21

Complete if Known	
Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		Cunningham, et al., "Human Monoclonal Antibodies Reactive with Antigens of the Group A Streptococcus and Human Heart," <u>Journal of Immunology</u> 141(8):2760-2766 (1988)	
		Dalldorf, et al., "The Lymphomas of Brazilian Children", <u>J. Am. Med. Assn.</u> , 208:1365-8 (1968)	
		Deacon, et al., "Frequency of EBV DNA Detection in Sjogren's Syndrome", <u>Am J. Med.</u> 92:453-454 (1992)	
		Deacon, et al., "Detection of Epstein-Barr Virus Antigens and DNA in Major and Minor Salivary Glands Using Immunocytochemistry and Polymerase Chain Reaction: Possible Relationship with Sjogren's Syndrome", <u>J. Pathol.</u> , 163:351-360 (1991)	
		DePolo, et al., "Continuing Coevolution of Virus and Defective Interfering Particles and of Viral Genome Sequences During Undiluted Passages: Virus Mutants Exhibiting Nearly Complete Resistance to Formerly Dominant Defective Interfering Particles," <u>J. of Virology</u> 61:454-464	
		Deutscher, et al., "Molecular Analysis of the 60-kDa Human Ro Ribonucleoprotein," <u>Proc. Natl. Acad. Sci. USA</u> 85:9479-83 (1988)	
		Dyrberg and Oldstone, "Peptides as Probes to Study Molecular Mimicry and Virus-Induced Autoimmunity," <u>Current Topics in Microbiology and Immunology</u> , 130:25-37 (1986)	
		Elkon, K., et al., "Epitope Mapping of Recombinant Herpes Simplex B' Peptides Obtained by the Polymerase Chain Reaction," <u>J. of Immun.</u> 145:636-643 (1990)	
		Esquivel, et al., "Induction of Autoimmunity in Good and Poor Responder Mice with Mouse Thyroglobulin and Lipopolysaccharide," <u>J. Exp. Med.</u> , 145:1250-1263 (1977)	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of 1/21/1999
LAC 5/5/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161

FEB 9 1998

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

6

of

21

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		Evans, "E.B. Virus Antibody in Systemic Lupus Erythematosus" <u>Lancet</u> , 1:1023-4 (1971)	
		Evans, et al., "Raised Antibody Titres to E.B. Virus in Systemic Lupus Erythematosus", <u>Lancet</u> , 1:167-168 (1970)	
		Evans & Rothfield, "E.B. Virus and Other Viral Antibodies in Systemic Lupus Erythematosus", <u>Lancet</u> , 1:1127-1128 (1973)	
		Evans & Niederman, Epstein-Barr virus, In <u>Viral Infections in Humans</u> , 3rd ed. Evans, A.S. ed. pp 265-292 (Plenum, New York City 1989)	
		Evans, et al., "E.B.V. Antibodies in Systemic Lupus Erythematosus", <u>Lancet</u> , 325-324 (1973)	
		Ferris and Donaldson, <u>Veterinary Microbiology</u> 18(34):243-258 (1988)	
		Finerty, et al., "Protective Immunization Against Epstein-Barr Virus-Induced Disease in Cottontop Tamarins Using the Virus Envelope glycoprotein gp340 Produced from a Bovine Papillomavirus Expression Vector", <u>J. Gen. Virol.</u> , 73:449-453 (1992)	
		Finerty, et al., "Vaccine", 12:1180-1184 (1994)	
		Fox, et al., "Potential Role of Epstein-Barr Virus in Sjogren's Syndrome and Rheumatoid Arthritis", <u>J. Rheumatol.</u> , 19:18-24 (1992)	
		Fox, "Sjogren's Syndrome", <u>Current Opin. Rheum.</u> , 7:409-416 (1995)	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of 1/21/1999
LAC 5/5/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161

Sheet 7 of 21

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue/number(s), publisher, cit and/or country where published	T ²
		Fox, et al., "Detection of Epstein-Barr Virus-Associated Antigens and DNA in Salivary Gland Biopsies from Patients with Sjogren's Syndrome", <u>J. Immunol.</u> , 137:3162-3168 (1986)	
		Fricke, H., et al., "Induction of Experimental Systemic Lupus Erythematosus in Mice by Immunization with a Monoclonal Anti-La Autoantibody," <u>Interv. Immunol.</u> 2:225-230 (1990)	
		Fritz, et al., "Small Nuclear U-Ribonucleoproteins in <i>Xenopus Laevis</i> Development," <u>J. Mol. Biol.</u> 178:273-285 (1984)	
		Gaither, et al., "Affinity Purification and Immunoassay of Anti-Ro/SSA" <u>Peptides Mol. Fluids</u> 33:413-416 (1985)	
		Gaither, et al., "Implications of Anti-Ro/Sjogren's Syndrome a Antigen Autoantibody in Normal Sera for Autoimmunity", <u>J. Clin. Invest.</u> , 79:841-846 (1987)	
		Gallione, et al., "Nucleotide Sequences of the mRNA's Encoding the Vesicular Stomatitis Virus N and NS Proteins," <u>Virology</u> 39:529-535 (1981)	
		Gergely, et al., "E.B.V. Antibodies in Systemic Lupus Erythematosus", <u>Lancet</u> , 1:325-326 (1973)	
		Geyser, et al., "Strategies for Epitope Analysis Using Peptide Synthesis,: <u>J. of Immunol. Meth.</u> , 102:259-274 (1987)	
		Geyser, et al., "Use of Peptide Synthesis to Probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid," <u>Proc. Natl. Acad. Sci. USA</u> 81:3998-4002 (1984)	
		Grabowski, et al., "Drosophila AP3, a Presumptive DNA Repair Protein, is Homologous to Human Ribosomal Associated Protein PO", <u>Nucleic Acids Research</u> , 19(15):4297 (1991)	
		Gu, et al., <u>Dev. Biol. Stand.</u> , 84:171-177 (1995)	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of 1/21/1999
LAC 5/5/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

FEB 9 1998

8 of 21

Complete if Known

Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		Guldner, et al., <u>The Journal of Immunology</u> , 141(2):469-475 (July 15, 1988)	
		Gutierrez, et al., "Switching Viral Latency to Viral Lysis: A Novel Therapeutic Approach for Epstein-Barr Virus-Associated Neoplasia", <u>Cancer Res.</u> , 56:969-972 (1996)	
		Haahr, et al., "A Putative New Retrovirus Associated with Multiple Sclerosis and the Possible Involvement of Epstein-Barr Virus in This Disease", <u>Ann. N. Y. Acad. Sci.</u> , 724:148-156 (1996)	
		Hahn, "Suppression of Autoimmune Diseases with Anti-idiotypic Antibodies: Murine Lupus Nephritis as a Model" <u>Springer Seminars in Immunopathology</u> , 7(1):25-34 (1984)	
		Hardgrave, et al, "Antibodies to Vesicular Stomatitis Virus Proteins in Patients with Systemic Lupus Erythematosus and in Normal Subjects," <u>Arthritis and Rheumatism</u> , 36(7):962-970	
		Harley & Gaither, "Autoantibodies" <u>Rheum. Dis. Clin. N. Amer.</u> , 14:43-56 (1992)	
		Harley, et al., "Anti-Ro (SS-A) and Anti-La (SS-B) in Patients with Sjogren's Syndrome", <u>Arthritis Rheum.</u> , 29:196-206 (1986)	
		Harley & James, "Review Articles: Autoepitopes in Lupus" <u>J. Lab. Clin. Med.</u> , 126(6):509-516 (1995)	
		Harley, et al., "Gene Interaction at HLA-DQ Enhances Autoantibody Production in Primary Sjogren's Syndrome," <u>Science</u> 232:1145-1147 (1986)	
		Herbert, et al., <u>Dictionary of Immunology</u> , 3rd Ed. Blackwell Scientific Publications Oxford UK page 14 91985)	
		Heslop, et al., "Long-Term Restoration of Immunity Against Epstein-Barr Virus Infection by Adoptive Transfer of Gene-Modified Virus-Specific T Lymphocytes", <u>Nature Med.</u> , 2:551-555 (1996)	

Examiner's Signature		Date Considered
----------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).- ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of 1/21/1999
LAC 5/5/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/PTO

Complete if Known

				Application Number	08/781,296
				Filing Date	January 13, 1997
				First Named Inventor	John B. Harley et al.
				Group Art Unit	Not yet assigned
				Examiner Name	Not yet assigned
Sheets	9	of	21	Attorney Docket Number	OMRF 161

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)



OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		Hinterberger, "Isolation of Small Nuclear Ribonucleoproteins Containing U1, U2, U4, U5, and U6 RNAs", <u>Biol. Chem.</u> , 258:2604-2618 (1983)	
		Hollinger, et al., "Seroepidemiologic Studies in Systemic Lupus Erythematosus", <u>Bact. Proc.</u> , 19:174 (1970)	
		Horsfall, et al., "Ro and La Antigens and Maternal Anti-La Idiotype on the Surface of Myocardial Fibers in Congenital heart Block," <u>J. Autoimmun.</u> , 4:165-176 (1991)	
		Huang, et al., "Human Anti-Ro Autoantibodies Bind Peptides Accessible to the Surface of the Native Ro Autoantigen," <u>Scand. J. Immunol.</u> , 41:220-228 (1995)	
		Huang, et al., "Immunization with Vesicular Stomatitis Virus Nucleocapsid Protein induces Autoantibodies to the 60 kD Ro Ribonucleoprotein Particle," <u>J. Investig. Med.</u> , 43:151-158 (1995)	
		Hurd, et al., "Formation of Leukocyte Inclusions in Normal Polymorphonuclear Cells Incubated with Synovial Fluid", <u>Arthritis Rheum.</u> , 13:724-33 (1970)	
		Inoue, et al., "Analysis of Antibody Titers to Epstein-Barr Virus Nuclear Antigens in Sera of Patients with Sjogren's Syndrome and with Rheumatoid Arthritis", <u>J. Infect. Dis.</u> , 164:22-28 (1991)	
		Ishii, et al., "Cycloheximide-Induced Apoptosis in Burkitt Lymphoma (BJA-B) Cells with and Without Epstein-Barr Virus Infection", <u>Immunol. Cell Biol.</u> , 73:463-468 (1995)	
		James, et al., "Basic Amino Acids Predominate in the Sequential Autoantigenic Determinants of the Small Nuclear 70K Ribonucleoprotein," <u>Scand. J. Immunol.</u> , 39:557-566 (1994)	
		James, et al., "Immunoglobulin Epitope Spreading and Autoimmune Disease After Peptide Immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP Induce Spliceosome Autoimmunity", <u>J. Exp. Med.</u> , 181:453-461 (1995)	
		James, et al., "Inbred Mice Strains Differ in Their Capacity to Develop Spliceosomal Autoimmunity After Peptide Immunization", <u>Arthritis Rheum.</u> , 38:S226 (1995)	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Not considered. Identical to the considered IDS of 1/21/1999
LAC 5/5/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)



Sheet 10 of 21

Complete if Known

Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		James & Harley, "Linear Epitope Mapping of an Sm B/B' Polypeptide", <u>J. Immunol.</u> , 148:2074-2079 (1992)	
		James & Harley, "Human Lupus Anti-Spliceosome A Protein Autoantibodies Bind Contiguous Surface Structures and Segregate into Two Sequential Epitope Binding Patterns", <u>J. Immunol.</u> , 4018-4026 (1996)	
		James, et al., "Lupus Humoral Autoimmunity After Short Peptipe Immunization", <u>Arthritis Rheum.</u> , 39:S216 (1996)	
		James & Harley, "Peptide Autoantigenicity of the Small Nuclear Ribonucleoprotein C", <u>Clin. And Exp. Rheum.</u> , 13:299-305 (1995)	
		James, et al., "Sequential Autoantigenic Determinants of the Small Nuclear Ribonucleoprotein Sm D Shared by Human Lupus Autoantibodies and MRL lpr/lpr Antibodies", <u>Clin. Exp. Immunol.</u> , 98:419-426 (1994)	
		James and Harley, "Sequential Fine Specificity of the Small Nuclear Ribonuclear Protein C", <u>Clinical Res.</u> , 41(2):PA393 (1993)	
		Kalush, et al., "Neonatal Lupus Erythematosus with Cardiac Involvement in Offspring of Mothers with Experimental Systemic Lupus Erythematosus", <u>J. of Clin. Immunol.</u> , 14:314-321 (1994)	
		Karameris, et al., "Detection of the Epstein Barr Viral Genome by an <i>in situ</i> Hybridization Method in Salivary Gland Biopsies from Patients with Secondary Sjogren's Syndrome", <u>Clin. Exp. Rheum.</u> , 10:327-332 (1992)	
		Kaufman, et al., "In Vivo Binding of Gram-Negative Bacterial Peptides to Hla-B27: A Possible Relationship to Ankylosing spondylitis Pathogenesis", UCLA School of Medicine (abstract)	
		Kieff & Liebowitz, D.: Epstein-Barr virus and its replication. In <u>Virology</u> , 2nd ed. Fields et al., eds. pp 1889-1921 (Raven Press, New York 1990)	

Examiner's Signature		Date Considered
----------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Not considered. Identical to the considered IDS of 1/21/1999
IAC 5/5/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 11 of 21

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		Kitagawa, et al., <u>Immunol. Lett.</u> , 17:249-252 (1988)	
		Klippel, et al., "Epstein-Barr Virus Antibody and Lymphocyte Tubuloreticular Structures in Systemic Lupus Erythematosus", <u>Lancet</u> , 2:1057-1058 (1973)	
		Kurilla, et al., "The Leader RNA of Vesicular Stomatitis Virus is Bound by a Cellular Protein Reactive with Anti-La Lupus Antibodies," <u>Cell</u> 34:837-845 (1983)	
		Kuzushima, et al., "Establishment of Anti-Epstein-Barr Virus (EBV) Cellular Immunity by Adoptive Transfer of Virus-Specific Cytotoxic T Lymphocytes from an HLA-matched Sibling to a Patient with Severe chronic Active EBV Infection", <u>Clin. Exp. Immunol.</u> , 103:192-298 (1996)	
		Larsen, et al., "Epstein-Barr Nuclear Antigen and Viral Capsid Antigen Antibody Titers in Multiple Sclerosis", <u>Neurology</u> , 35:435-438 (1985)	
		Lazarovots, et al., "Anti-B Cell Antibodies for the Treatment of Monoclonal Epstein-Barr Virus-Induced Lymphoproliferative Syndrome After Multivisceral Transplantation", <u>Clin. Invest. Med.</u> , 17:621-625 (1994)	
		Lerner & Steitz, "Antibodies to Small Nuclear RNAs Complexed with Proteins are Produced by Patients with Systemic Lupus Erythematosus", <u>Proc. Natl. Acad. Sci. USA</u> , 76:5498-5499 (1979)	
		Lee, et al., "Cardiac Immunoglobulin Deposition in Congenital heart Block Associated with Maternal Anti-Ro Autoantibodies," <u>Am. J. of Med.</u> 83:793-796 (1987)	
		Lee, et al., "The Recognition of Human 60-kDa Ro Ribonucleoprotein Particles by Antibodies Associated with Cutaneous Lupus and Neonatal Lupus", <u>J. Investigative Dermatology</u> , 107(1):225-228 (1996)	
		Lehman, et al., "Spreading of T-Cell Autoreactivity to Cryptic Determinants of an Autoantigen," <u>Nature</u> 356:155-157 (1992)	
		Lerner, et al., "Are snRNPs Involved in Splicing?" <u>Nature</u> 283:220-224 (1980)	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw lines through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of 1/21/1999
LAC 5/5/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 12 of 21

Complete if Known

Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue/number(s), publisher, cit and/or country where published	T ²
		Leif, "Maverick Herpes Receptor Sparks Search for KS Drug", <u>Bio World Today</u> , 8(17):1 (1997)	
		Levitskaya, "Inhibition of Antigen Processing by the Internal Repeat Region of the Epstein-Barr Virus Nuclear Antigen-1", <u>Nature</u> , 375:685-688 (1995)	
		Maddison, et al., "Quantitation of Precipitating Antibodies to Certain Soluble Nuclear Antigens in SLE," <u>Arthritis Rheum.</u> 20:819-824 (1977)	
		Maitland, "Frequency of EBV-DNA Detection in Sjogren's Syndrome", <u>Am. J. Med.</u> 96:97 (1994)	
		Manfredi, et al., "Molecular Anatomy of an Autoantigen: T and B Epitopes on the Nicotinic Acetylcholine Receptor in Myasthenia Gravis," <u>J. Lab. Clin. Med.</u> 120:13-21 (1992)	
		Mariette, et al., "Detection of Epstein-Barr Virus DNA by <i>in Situ</i> Hybridization and Polymerase Chain Reaction in Patients with Sjogren's Syndrome", <u>Am. J. Med.</u> , 90:286-294 (1991)	
		Matter, et al., "Molecular Characterization of Ribonucleoprotein Antigens Bound by Antinuclear Antibodies," <u>Arthritis Rheum.</u> 25:1278-1283 (1982)	
		Mattioli, et al. "Physical Association of Two Nuclear Antigens and Mutual Occurrence of Their Antibodies: The relationship of the Sm and RNA protein (MO) Systems in SLE Sera," <u>J. Immunol.</u> 110:1318-1324 (1973)	
		McAllister, G., et al., "cDNA Sequence of the rat U snRNP-associated Protein N: Description of a Potential Sm Epitope," <u>EMBO Jour.</u> 8:1177-1181 (1989)	
		Mendlovic, S., et al., "The Genetic Regulation of the Induction of Experimental SLE," <u>Immunology</u> 69:228-236 (1990)	
		Mendlovic, S., et al., "The Role of Anti-Idiotypic Antibodies in the Induction of Experimental Systemic Lupus Erythematosus in Mice," <u>Eur. J. Immunol.</u> 19:729-732 (1989)	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of 1/21/1999
LAC 5/5/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

FEB 9 1998



SEARCHED

INDEXED

SERIALIZED

FILED


SEARCH

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)



Sheet of 14

of

21

Complete if Known	
Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		Newkirk, et al., "Detection of Cytomegalovirus, Epstein-Barr Virus and Herpes Virus-6 in Patients with Rheumatoid Arthritis With or Without Sjogren's Syndrome", <u>Br. J. Rheum.</u> , 33:317-322 (1994)	
		Nider, et al., <u>PNAS</u> 87:9933 (1990)	
		Ohosone, et al., "Molecular Cloning of cDNA Encoding Sm Autoantigen. Derivation of a cDNA for a B Polypeptide of the U Series of Small Nuclear Ribonucleoprotein Particles," <u>Proc. Natl. Acad. Sci. USA</u> 86:4249-4253 (1989)	
		Palfi, et al., "Purification of the Major UsnRNPs from Broad Bean Nuclear Extracts and Characterization of their Protein Constituents," <u>Nucleic Acids Res.</u> 17:1445-1458 (1989)	
		Petersen, et al., "Altered Immune Response to Glycine-Rich Sequences of Epstein-Barr Nuclear Antigen-1 in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus", <u>Arthritis Rheum.</u> , 33: 993-1000 (1990)	
		Petterson, et al., "The Structure of Mammalian Small Nuclear Ribonucleoproteins", <u>J. Biol. Chem.</u> , 259:5907-5914 (1984)	
		Pflugfelder, et al., "Epstein-Barr Virus and the Lacrimal Gland Pathology of Sjogren's Syndrome", <u>Am. J. Pathol.</u> , 143:49-64 (1993)	
		Pflugfelder, et al., "Amplification of Epstein-Barr Virus Genomic Sequences in Blood Cells, Lacrimal Glands, and Tears from Primary Sjogren's Syndrome Patients", <u>Ophthalmology</u> , 97:976-984 (1990)	
		Phillips & Christian, "Myxovirus Antibody Increases in Human Connective Tissue Disease", <u>Science</u> , 168:982-4 (1970)	
		Phillips, et al., "Viruses and Systemic Lupus Erythematosus", <u>Lancet</u> , 1:449 (1973) Quagliere & Pearson, "Radioimmune Precipitation Study Comparing the Epstein-Barr Virus Membrane Antigens Expressed on P3HR-1 Virus-Superinfected Raji Cells to those Expressed on Cells in a B-95 Virus-Transformed Producer Culture Activated with Tumor	
		Query, et al., "A Common RNA Recognition Motif Identified within a Defined U1 RNA Binding of the 70K U1 snRNP Protein," <u>Cell</u> 57:89-101 (1989)	

Examiner's Signature	Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §09. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of 1/21/1999
IAC 5/5/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)



Sheet 15 of 21

Complete if Known

Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned

Attorney Docket Number OMRF 161

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue-number(s), publisher, cit and/or country where published	T ³
		Ravirajan & Staines, "Involvement in Lupus Disease of Idiotypes Id.F-423 and Id.IV-228 Defined, Respectively, Upon Foetal and Adult MRL/Mp-lpr/lpr DNA-binding Monoclonal Autoantibodies" <u>Immunology</u> , 74:342-347 (1991)	
		Reichlin, et al., "Autoantibodies to the URNP Particles: Relationship to Clinical Diagnosis and Nephritis," <u>Clin. Exp. Immunol.</u> 83:286-290 (1991)	
		Reichlin, et al., "Concentration of Autoantibodies to native 60-kd Ro/SS-A and Denatured 52-kd Ro/SS-A in Eluates from the Heart of a Child Who Died with Congenital Complete Heart Block," <u>Arth. And Rheum.</u> 37:1698-1703 (1994)	
		Renz, M., et al., "Expression of the Major Human Ribonucleoprotein (RNP) Autoantigens in <i>Escherichia coli</i> and their Use in an EIA for Screening Sera from Patients with Autoimmune Diseases," <u>Clin. Chem.</u> 35:1861-1863 (1989)	
		Reuter, et al., <u>PNAS</u> 83:8689-8693 (1986)	
		Rhodes, et al., "Autoantibodies in Infectious Mononucleosis Have Specificity for the Glycine-Alanine Repeating Region of the Epstein-Barr Virus Nuclear Antigen", <u>J. Exp. Med.</u> , 165:1026-1040 (1987)	
		Rokeach, et al., "Molecular Cloning of a cDNA Encoding the Human Sm-D Autoantigen," <u>Proc. Natl. Acad. Sci. USA</u> 85:4832-36 (1988)	
		Rokeach, et al., "Primary Structure of a Human Small Nuclear Ribonucleoprotein Polypeptide as Deduced by cDNA Analysis", <u>J. Biol. Chem.</u> , 264:5024-30 (1989)	
		Rose, et al., "T-Cell Regulation in Autoimmune Thyroiditis," <u>Immuno. Reviews</u> 55:229-314 (1981)	
		Rose, et al., "Genetic Regulation in Autoimmune Thyroiditis," Talal N. et al. <u>Autoimmunology Genetic Immunologic Virologic, and Clinical Aspects</u> . New York: Academic Press, 63-87 (1977)	
		Rose, et al., "Studies on Experimental Thyroiditis," <u>Ann. NY Acad. Sci.</u> 124:201-108 (1965)	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Not considered. Identical to the considered IDS of 1/21/1999
LAC 5/5/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)



Sheet

16

of

21

Complete if Known	
Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		Sabbatini, et al., "Autoantibodies from Patients with Systemic Lupus Erythematosus Bind a Shared Sequence of AmyD and Epstein-Barr Virus-Encoded Nuclear Antigen EBNA I", <u>Eur. J. Immunol.</u> , 23:1146-1152 (1993)	
		Saito, et al., "Detection of Epstein-Barr Virus DNA by Polymerase Chain Reaction in Blood and Tissue Biopsies from Patients with	
		Sasaki, et al., "In Vitro Manipulation of Human Anti-DNA Antibody Production by Anti-idiotypic Antibodies Conjugated with Neocarzinostatin", <u>The Journal of Immunology</u> , 142(4):1159-1165 (1989)	
		Schaack, "Molecular Mimicry in HLA-B-27-Related Arthritis," <u>Annals of Internal Medicine</u> , 111(7):581-591 (October 1, 1989)	
		Schmauss, et al., "A Comparison of snRNP-Associated Sm-Autoantigens: Human N, Rat N and Human B/B (abstract)", <u>Nuc. Acid Res.</u> , 17:1733-43 (1989)	
		Schoenfeld, et al, "Modulation of Experimental SLE Induced in Naive Mice by a Pathogenic Anti-DNA Idiotype (16/6 Id)," <u>Proceedings of the Second International Conference on Systemic Lupus Erythematosus</u> Tokyo, Japan Professional Postgraduate Services 83 (1989)	
		Schoenfeld, et al, "Pathogenic Idiotypes of Autoantibodies in Autoimmunity: Lessons from New Experimental Models of SLE," <u>FASEB J.</u> 4:2646-2651 (1990)	
		Scofield, et al., "60kD Ro/SSA Autoepitopes are Found in Regions of Homology Between Ro/SSA and the Nucleocapsid Protein of Vesicular Stomatitis Virus," <u>Arthritis and Rheumatism</u> , 33(9):3101 (1990)	
		Scofield, et al., "Autoantigenicity of Ro/SSA Antigen is Related to a Nucleocapsid Protein of Vesicular Stomatitis Virus", <u>Proc. Natl. Acad. Sci. USA</u> , 88:3343-3347 (1991)	
		Scofield, R., "A Common Autoepitope Near the Carboxyl Terminus of the 60-kD Ro Ribonucleoprotein: Sequence Similarity with a Viral Protein," <u>Journal of Clinical Immunology</u> 11(6):378-388 (1991)	
		Scofield, et al., "The Autoantigenicity of Human 60kD Ro/SSA is Related to Homologies Between Ro/SSA and the Nucleocapsid Protein of Vesicular Stomatitis Virus," <u>Clinical Research</u> , 38(2):316A, (1990)	
		Scofield, et al., "Development of the Anti-Ro Autoantibody Response in a Patient with Systemic Lupus Erythematosus", <u>Arthritis & Rheumatism</u> , 39(10):1664-1688 (1996)	

Examiner's Signature		Date Considered
----------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of 1/21/1999
LAC 5/5/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

17

of

21

Complete if Known	
Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		Scofield, et al., "Immunization with Short Peptides from the Sequence of the Systemic Lupus Erythematosus-Associated 60-kDa Ro Autoantigen: Results in Anti-Ro Ribonucleoprotein Autoimmunity", <u>J. Immunology</u> , 4059-4066 (1990)	
		Scofield, "Autoimmune Thyroid Disease in Systemic Lupus Erythematosus and Sjogren's Syndrome", <u>Clin. Exp. Rheum.</u> , 14:321-330 (1996)	
		Scofield, "HLA-B27 Binding of Peptide From Its Own Sequence and Similar Peptides From Bacteria: Implications For Spondyloarthropathies", <u>Lancet</u> , 345:1542-1544 (1995)	
		Sculley, et al., "Reactions of sera from Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus and Infectious Mononucleosis to Epstein-Barr Virus-Induced Polypeptides", <u>J. Gen. Virol.</u> , 67:2253-2258 (1986)	
		Sharpe, et al., "Isolation of cDNA Clones Encoding the Human Sm B/B' Auto Immune Antigen and Specifically Reacting with Human Anti-Sm Auto-", <u>FEBS Lett.</u> , 250:585-590 (1989)	
		Sillikens, et al., "Human U1 snRNP-specific C Protein: Complete cDNA and Protein Sequence and Identification of a Multigene Family in Mammals", <u>Nucleic Acids Res.</u> , 16:8307-21 (1988)	
		Sillikens, P., et al, "cDNA Cloning of the Human U1 snRNA-Associated A Protein: Extensive Homology Between U1 and U2 snRNP-Specific Proteins", <u>EMBO Journal</u> 6:3841-3848 (1988)	
		Singh, et al., "Decreased Incidence of Viral Infections in Liver Transplant Recipients - Possible Effects of FK506?", <u>Digestive Dis. Sci.</u> , 39:15-18 (1994)	
		Spritz, et al, "The Human U1-70K s.n. RNP Protein: cDNA Cloning, Chromosomal Localization, Expression, Alternative Splicing and RNA-binding", <u>Nucleic Acid Res.</u> , 15:10373-91 (1987)	
		Sturgess, A., et al., "Characteristics and Epitope Mapping of a Cloned Human Autoantigen La", <u>J. Immun.</u> , 3212-3218 (1988)	
		Sumaya, et al., "Increased Prevalence and Titer of Epstein-Barr Virus Antibodies in Patients with Multiple Sclerosis", <u>Ann. Neurol.</u> , 17:371-377 (1985)	

Examiner's Signature	Date Considered
----------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Not considered. Identical to the considered IDS of 1/21/1999
LAC 5/5/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)



Sheet

18

of

21

Complete if Known	
Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		Suzuki, et al., "Viral Interleukin 10 (IL-10), the Human Herpes Virus 4 Cellular IL-10 Homologue, Induces Local Anergy to Allogeneic and Syngeneic Tumors", <u>J. Exp. Med.</u> , 182:477-486 (1995)	
		Takeda, Y., et al., "Antigenic Domains on the U1 Small Nuclear Ribonucleoprotein-associated 70kD Polypeptide; a comparison of regions selectively recognized by Human and Mouse Autoantibodies and by Monoclonal Antibodies," <u>Chem. Abstracts</u> 116(1): ab. No. 4803a (January 6, 1992)	
		Tan, et al., "The 1982 Revised Criteria for the Classification of Systemic Lupus Erythematosus", <u>Arthritis Rheum.</u> , 25:1271-1277 (1982)	
		Tan, et al., "Characteristics of Soluble Nuclear Antigen Precipitating with Sera of Patients with Systemic Lupus Erythematosus," <u>J. Immunol.</u> , 96:464-471 (1966)	
		Tateishi, et al., "Spontaneous Production of Epstein-Barr Virus by B Lymphoblastoid Cell Lines Obtained from Patients with Sjogren's Syndrome", <u>Arthritis Rhuem.</u> , 36:827-835 (1993)	
		Theissen, et al., "Cloning of the Human cDNA for the U1 RNA-associated 70K Protein," <u>EMBO J.</u> 5:3209-17 (1986)	
		Tigbe, <u>Production of Human Rheumatoid Factors (RF) by SCID Mice Transplanted with Synovial Membrane Lymphocytes</u> , presented at the Arthritis Foundation Fellows Conference, Amelia Island, Plantation, Florida, December 8-10 (1989)	
		Tincani, et al., "Induction of Experimental SLE in Naive Mice by Immunization with Human Polyclonal anti-DNA Antibody Carrying the 16/6 Idiotype," <u>Clinical and Exp. Rheum.</u> , 11:129-134 (1993)	
		Toda, et al., <u>Sjogren's syndrome (SS) and Epstein-Barr virus (EBV) reactivation. In Lacrimal Gland, Tear Film, and Dry Eye Syndrome</u> . D.A. Sullivan, ed. pp 647-650 (Plenum Press, New York 1994)	
		Tsai, et al., "Detection of Epstein-Barr Virus and Cytomegalovirus Genome in White Blood Cells from Patients with Juvenile Rheumatoid Arthritis and Childhood Systemic Lupus Erythematosus", <u>Int. Arch. Allergy Immunol.</u> , 106:235-240 (1995)	
		Tsuzuka, et al., "Lupus Autoantibodies to Double-stranded DNA Cross-react with Ribosomal Protein S1", <u>Arthritis & Rheumatism</u> , 38(9):abstract 726 (1995)	

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of 1/21/1999
LAC 5/5/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161

FEB 9 1997
PATENT & TRADEMARK OFFICE

CIPR INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

19

of

21

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, cit and/or country where published	T ²
		Tzartos, et al., Autoimmunity 8:259-270 (1991)	
		van Dam, et al., "Cloned Human snRNP Proteins B and B' Differ Only in Their Carboxy-Terminal Part", EMBO J., 8(12):3853-3860 (1989)	
		Van Venrooij, et al., "B Cell Epitopes on Nuclear Autoantigens," Arthritis and Rheumatism 37(5):608-616 (1994)	
		Venables, et al., "Persistence of Epstein-Barr Virus in Salivary Gland Biopsies from Healthy Individuals and Patients with Sjogren's Syndrome", Clin. Exp. Immunol., 75:359-364 (1989)	
		Venables, et al., "The Response to Epstein-Barr Virus Infection in Sjogren's Syndrome", J. Autoimmunity, 2:439-448 (1989)	
		Virji and Heckels, "Location of a Blocking Epitope on Outer-membrane Protein III of Neisseria Gonorrhoeae by Synthetic Peptide Analysis," J. of Gen. Microbiol. 135:1895-1899 (1989)	
		Voller and Bidwell, "Enzyme-Linked Immunosorbent Assay," Manual of Clinical Laboratory Immunology (Chapter 17) (1986)	
		Wait, K., et al., "Anti-Jo-1 antibodies are Directed at an Evolutionarily-conserved Conformational Site on Human Histidyl-tRNA Synthetase," Mol. Cell Biol. Autoantibodies Autoimmun. 100-101. (1989)	
		Wagstaff, et al., Drugs, 47:153-205 (1994)	
		Waltuck and Buyon, "autoantibody-associated Congenital Heart Block: Outcome in Mothers and Children," Ann. Intern. Med. 120:544-551 (1994)	
		Warner & Carp, "Multiple Sclerosis Biology - an Epstein-Barr Virus Hypothesis" Med. Hypotheses, 25:93-97 (1988)	

Examiner's Signature		Date Considered
----------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Not considered. Identical to the considered IDS of 1/21/1999
LAC 5/5/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

20

of

21

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue-number(s), publisher, cit and/or country where published	T ²
		Watson, et al., "Certain Properties Make Substances Antigenic," in <u>Molecular Biology of the Gene</u> , Fourth Edition, page 836, paragraph 3, The Benjamin/Cummings Publishing Company, Menlo Park, 1987)	
		Whittingham, et al., "Epstein-Barr Virus as an Etiological Agent in Primary Sjogren's Syndrome," <u>Med Hypothesis</u> , 22:373-386 (1987)	
		Williams, et al., "A Repeated Proline-rich Sequence in Sm B/B' and N is a Dominant Epitope Recognized by Human and Murine Autoantibodies," <u>J. Autoimmunity</u> 3:715-725 (1990)	
		Wilson, et al., "Association of Lymphomatoid Granulomatosis With Epstein-Barr Viral Infection of B Lymphocytes and Response to Interferon- α 2b," <u>Blood</u> , 87:4531-4537 (1996)	
		Winfield, et al., "Serologic Studies in patients with Systemic Lupus Erythematosus and Central Nervous System Dysfunction," <u>Arthritis Rheum.</u> 21:289-294 (1978)	
		Witebsky, et al., "Chronic Thyroiditis and Autoimmunization," <u>J. Am. Med. Assoc.</u> , 164:1439-1447 (1957)	
		Xie & Snyder, "Two Short Autoepitopes on the Nuclear Dot Antigen Are Similar to Epitopes Encoded by the Epstein-Barr Virus", <u>Proc. Natl. Acad. Sci.</u> , 92:1639-1643 (1995)	
		Yamamoto, K., et al., "Isolation and Characterization of a Complementary DNA Expressing Human U1 Small Nuclear Ribonucleoprotein C Polypeptide," <u>J. Immun.</u> 140:313-317 (1988)	
		Yokochi, et al., "Hight Titer of Antibody to the Epstein-Barr Virus Membrane Antigen in Sera from Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus", <u>J. Rheumatol.</u> , 16:1029-1039 (1989)	
		Zeller, et al., "Nucleocytoplasmic Distribution of snRNPs and Stockpiled snRNA-Binding Proteins During Oogenesis and Early Development in Xenopus laevis," <u>Cell</u> 32:425-434 (1983)	

Examiner's Signature		Date Considered
----------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Not considered. Identical to the considered IDS of
1/21/1999

LAC 5/5/08ot considered. Identical to the considered IDS of
1/21/1999
LAC 5/5/08

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

21 of 21

Complete if Known	
Application Number	08/781,296
Filing Date	January 13, 1997
First Named Inventor	John B. Harley et al.
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	OMRF 161

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Signature _____ **Date Considered** _____

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

~~Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.~~

Not considered. Identical to considered IDS of 1/21/1999
LAC 5/5/08